From bedside to bench and back : future options for antiretroviral drugs in non-B HIV-1 subtypes by Njenda, Duncan Tazvinzwa
From Department of Laboratory Medicine
Karolinska Institutet, Stockholm, Sweden
FROM BEDSIDE TO BENCH AND BACK: 
FUTURE OPTIONS FOR  ANTIRETROVIRAL 
DRUGS IN NON-B HIV-1 SUBTYPES
Duncan Tazvinzwa Njenda
Stockholm 2020
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Arkitektkopia AB, 2020 
© Duncan Tazvinzwa Njenda, 2020 
ISBN 978-91-7831-713-4
Principal Supervisor:
Associate Professor Ujjwal Neogi 
Karolinska Institutet 
Department of Laboratory Medicine 
Division of Clinical Microbiology
Co-supervisors:
Professor Susan Engelbrecht 
Stellenbosch University, South Africa 
Faculty of Medicine and  
Health Sciences 
Department of Pathology, 
Division of Medical Virology
Professor Anders Sönnerborg 
Karolinska Institutet, Sweden 
Department of Laboratory Medicine 
Division of Clinical Microbiology
Dr Graeme Brendon Jacobs 
Stellenbosch University 
Faculty of Medicine and  
Health Sciences 
Department of Pathology, 
Division of Medical Virology
Professor Anna-Lena Spetz 
Stockholm University 
Department of Molecular Biosciences,  
Wenner-Gren Institute
Opponent:
Associate Professor Zabrina Brumme 
Simon Fraser University 
Faculty of Health Sciences 
British Columbia Centre for Excellence 
in HIV/AIDS
Examination Board:
Associate Professor Maria (Mia) Brytting 
The Public Health Agency of Sweden 
Department of Microbiology 
Division of Virology
Associate Professor Jonas Klingström 
Karolinska Institutet 
Department of Medicine 
Center of infectious Medicine (CIM)
Dr Andre Gareth Loxton 
Stellenbosch University, South Africa 
Faculty of Medicine and Health Sciences 
Division of Molecular Biology and  
Human gentics
Professor Jan Stefan Gustav Schwartz 
Lund University, Sweden 
Department of Laboratory Medicine 
Division of Medical Microbiology
Associate Professor Harold Marcotte 
Karolinska Institutet 
Department of Laboratory Medicine 
Division of Clinical Immunology
From bedside to bench and back: 
Future options for antiretroviral drugs 
in non-B HIV-1 subtypes
THESIS FOR DOCTORAL DEGREE (Ph.D.)
The thesis will be defended at Ana Futura, plan 4, room 4X,  
Karolinska Institutet, Campus Flemingsberg, Huddinge
Friday, February 28, 2020, at 10.00 am
By
Duncan Tazvinzwa Njenda

“39:4.13 – Urantia Book There is no material reward for righteous living, 
but there is profound satisfaction – consciousness of achievement – and  
this transcends any conceivable material reward.”
I dedicate this to my family, friends, and most importantly,  
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ABSTRACT
HIV-1 drug resistance remains a burden in low- and middle-income countries (LMIC). 
Regardless of the advances in antiretroviral (ARV) therapy, there is an increase in 
the trend of acquired and pre-treatment drug resistance mutations (DRM) in LMIC 
affected by diverse HIV-1 subtypes. 
In the work presented in this thesis, I investigated the prevalence of HIV-1 acquired drug 
resistance (ADR) in South Africa from the period 2006-2014 (Paper I). Additionally, 
the in vitro protease- inhibitor (PI) drug sensitivity assay (DSA) response of HIV-1 
subtype C (HIV-1C) derived recombinant viruses was compared to non-C viruses 
to understand their susceptibility profile to PI drugs. Results for the prevalence of 
ADR, specifically for patient sequences treated with a PI-based regimen (n=1043), 
was found to be <9%. No significant subtype-specific differences were seen for 
viruses tested in the DSA for Darunavir (DRV), Lopinavir (LPV) and Atazanavir 
(ATV) susceptibility. In Paper II, it was hypothesized that the gag gene could play 
a role in the response of PIs in the absence of known PI primary mutations. Hence to 
understand the role of Gag in impacting PI susceptibility and viral fitness, the gag-p6 
region was specifically investigated. The study showed an increase in viral fitness 
for HIV-1C viruses carrying the PYxE insertion in gag-p6 when compared to the 
wild-type (WT) HIV-1C viruses. Furthermore, some PYxE-carrying viruses had low 
sensitivity to LPV and Tenofovir alafenamide (TAF) when tested in DSAs. Clinical 
data analysis, showed a higher pre-therapy viral load and a decrease in CD4+ T-cell 
counts for patients harboring PYxE-carrying viruses when compared to WT. It was 
also essential to understand the inhibitory potential of most clinical (new and old) 
drugs used mainly to treat non-B HIV-1 subtypes. Hence, in Paper III, the newer 
antiretroviral drug 4’-Ethynyl-2’-Fluoro-2’ deoxyadenosine (EFdA), was compared 
to TAF, first and second-generation non-nucleoside reverse transcriptase inhibitors 
(NNRTIs). It was demonstrated that EFdA has a high inhibitory potential independent 
of HIV-1 subtype and high antiviral  activity against resistant viruses. However, HIV-1C 
viruses had a significantly reduced susceptibility to NNRTIs, specifically Rilpivirine 
and Etravirine. Finally in Paper IV, the drug susceptibility of Integrase strand transfer 
inhibitors (INSTIs) against diverse HIV-1 subtypes was investigated. Results indicated 
that INSTIs such as Dolutegravir (DRV), Bictegravir (BIC) and Cabotegravir (CAB) 
inhibited non-B subtypes significantly as compared to HIV-1B subtypes. 
Finally, inferences suggest that subtype-specific differences play an essential role in 
influencing the ARV susceptibility which could further impact the treatment efficacy 
in sub-optimal adherence. To reduce the trend of increasing DRMs in non-B HIV-1 
subtypes which are mainly dominating in LMICs, adherence support and viral load 
monitoring should be prioritized. A rapid adaptation of INSTIs and newer drugs that 
have long-acting potential is encouraged. However, pre-clinical studies and clini-
cal trials that are mainly restricted to HIV-1B enrolled patients, should be inclusive 
of non-HIV-1B infected patients before the massive roll-out of INSTIs and newer 
drugs continues in non-HIV-1B dominated settings.
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11 INTRODUCTION
Human immunodeficiency virus (HIV) drug resistance remains a challenge for 
the management of HIV-infected patients under combination antiretroviral therapy 
(cART) (1). Globally, Sub-Saharan Africa (SSA) is the region with the highest 
prevalence of HIV and with the most significant challenge in the management of 
HIV infections, as recently reported by the World Health Organization (WHO) 
(2). There has also been a substantial increase in the pre-treatment and acquired 
HIV-1 drug resistance rates across the 48 countries that comprise SSA. This 
chapter presents an overview of the replication cycle of HIV-1 and the different 
antiretroviral (ARV) drugs used to treat HIV-1. The end of the chapter, describes 
a conspectus of the epidemiology and drug resistance situation in South Africa 
and Sweden as the two main countries from which HIV-1 patient material was 
used for the different studies mentioned in this thesis. The samples obtained from 
both countries represent some of the HIV-1 non-B subtypes (HIV-1B) that are a 
burden to SSA and globally. 
1.1 HIV-1 replication cycle 
HIV-1 is an RNA retrovirus approximately 100-120nm in diameter and targets host 
immune cells for its replication (3). Genetically, HIV-1 consists of three structural 
genes (gag, pol, and env); two non-structural regulatory genes (tat, rev) and four 
non-structural accessory genes (vif, vpr, vpu, and nef) (4-6). The three structural 
genes – gag, pol and env – encode the Gag capsid proteins, viral enzymes (Protease, 
Reverse Transcriptase and Integrase) and Env proteins respectively, that constitute 
the infectious viral particle (Figure 1)(7). 
Figure 1. HIV replication cycle and drug targets. [Image reproduced with permission from 
Springer Nature and adapted from Nature Reviews (7)]
2HIV transmission occurs via multiple routes that include heterosexual and homo-
sexual intercourse, needle-stick injuries, transfusion with contaminated blood, and 
vertical transmission (Mother-to-child transmission- MTCT) (8-10). 
Upon an individual’s infection with HIV, the replication cycle of the virus initi-
ates when its envelope glycoproteins (gp120 and 41) facilitate its attachment to 
the CD4 receptor (primarily present on T- lymphocytes) (11) and the co-receptor 
(CCR5/ CXCR-4) (12) on the host cell membrane. Attachment of the virus leads 
to a fusion-dependent event with the host cell membrane that allows docking of 
the viral RNA genome into the cytoplasm (13). The viral RNA is then reverse tran-
scribed into double-stranded complementary DNA (cDNA), and the cDNA then 
associates with host factors as well as the viral Integrase enzyme to form the pre-
integration complex (PIC) (14). The PIC is then transported into the cell nucleus 
where the viral integrase enzyme enacts a strand transfer reaction that results in 
the integration of the viral genome into the host cell genome (15). The presence 
of the viral protein Tat (Transactivator of transcription) and host cell transcription 
factors lead to the expression of viral mRNA. After post-transcriptional modifica-
tion and translation of  viral mRNA, viral proteins are produced (16).
Viral proteins are then transported to the inner membrane via interaction with the 
endosomal sorting complex required for transport (ESCRT) machinery (17). The 
assembly of immature virions begins near the host cell inner membrane before 
they bud off and through cleavage events by the viral protease, emerge as infec-
tious particles to enter the plasma or can be transmitted from cell to cell (18) to 
start another round of infection. In an untreated HIV infected patient, the number 
of viral particles released in a day could be as high as 10000 particles per cell 
(19). Sometimes the virus may remain transcriptionally silent after integration in 
the infected cell and establishes a latent reservoir (primarily in CD4 central and 
transitional memory T-cells) (20). HIV-1 latency is the reason why HIV-1 patients 
receiving ARV treatment can not be completely cured (21).
1.2 HIV drug targets and ARV classes
The main steps of HIV viral replication include binding and entry, reverse tran-
scription, integration, viral assembly, and budding. These steps form the basis for 
the targets of the 6 different ARV drug classes (Nucleos(t)ide reverse transcriptase 
inhibitors (NRTIs), Non- Nucleoside reverse transcriptase inhibitors (NNRTIs), 
Protease inhibitors (PIs), Integrase strand transfer inhibitors (INSTIs) and entry 
inhibitors (sub-divided as fusion inhibitors (FI) and inhibitors of co-receptor usage), 
Table 1. In total there are 31 United States of America (USA) Federal Drug Agency 
(FDA) approved HIV ARVs currently being marketed and the brand names of their 
co-formulated products are also given below in Figure 2 (22).
3Figure 2. FDA approved antiretroviral drugs for HIV treatment shown to act on different 
stages of the HIV-1 replication cycle
Table 1. FDA approved Fixed-dose antiretroviral drugs for HIV currently marketed
Fixed-dose combinations
Atripla (EFV+ FTC+TDF) Prezcobix (DRV + Cobicistat)
Stribild (EVG + TDF + Cobicistat + FTC) Trizivir (ABC +3TC +AZT)
Truvada (TDF + FTC) Genvoya (EVG + cobicistat + FTC + TAF)
Triumeq (ABC + DTG + 3TC) Biktarvy (BIC + FTC+TAF)
Complera (FTC + RPV + TDF) Symtuza (DRV+ FTC +TAF + Cobicistat)
Combivir (3TC + AZT) Dovato (DTG + 3TC)
Descovy (FTC + TAF) Juluca (DTG + RPV)
Evotaz (ATV + Cobicistat) Delstrigo (DOR + 3TC + TDF)
Epzicom (3TC + ABC) Symfi (lo) (EFV +3TC +TDF)
Odefsey (FTC + TAF + RPV) Cimduo (Temixys+ 3TC+TDF)
41.3 Mechanism of action of different ARVs
The classes of ARVs have different mechanisms of action that will be described 
below:
1.3.1  Nucleos(t)ide reverse transcriptase inhibitors (NRTIs)
NRTIs enter the cell by passive diffusion or are transported by a variety of carrier 
and ATP-dependent mediated membrane transporters. The most characterized 
membrane proteins for the transport of NRTIs are multidrug resistance proteins 
(MRPs) (23). Upon entering the cell cytoplasm, NRTIs are phosphorylated by the 
action of phosphotransferases and cellular kinases into triphosphate forms (24). 
NRTI triphosphate forms actively compete with the cell’s natural dNTP substrates 
at HIV-1 RT’s polymerase active site for incorporation into the growing cDNA 
strand synthesized by the HIV-1 RT enzyme. Once incorporated the triphosphate 
forms cause premature chain termination as they lack a 3’-OH group that would 
have facilitated the incorporation of the next dNTP substrate (25).
1.3.2 Non-Nucleoside reverse transcriptase inhibitors (NNRTIs)
NNRTIs do not have to be metabolized in the cell to gain activity against HIV-1. 
They gain cellular entry by passive diffusion as highly lipophilic molecules (26). 
They have been proposed to have three different mechanisms of action that express 
antiviral activity. The first classical mechanism is that of allosteric inhibition – 
NNRTIs bind in an HIV-RT pocket region that is 10Å away from the polymerase 
active site and cause a conformational change in HIV-RT affecting its ability to 
bind to the primer during reverse transcription (27). 
The second mechanism (although controversial), involves inhibition effects on 
HIV-1 RT heterodimer formation. The inhibition restricts the enzyme’s activity 
to simultaneous execute its polymerase and RNA degradation functions (26, 28). 
The third mechanism is believed to be an acceleration of cytoplasmic Gag-Pol 
processing by premature activation of the HIV-1 Protease enzyme. Premature 
activation of protease is hypothesized to occur when binding of NNRTIs to Gag-
Pol proteins occurs, which then promotes oligomerization of the pol molecules 
by binding to the p66 subunit of HIV-RT. Premature cleavage of these Gag-Pol 
constructs restricts proteins required for viral particle assembly (26).
1.3.3 Protease Inhibitors (PIs)
PI cellular uptake can be via passive diffusion or mediated by Clathrin / Caveolae 
endocytic pathways (29). The tight binding interactions of PI on the dimer surface 
of the homodimer HIV-1 protease active site inhibits the enzyme’s functioning 
to execute aspartic acid-mediated cleavage of its substrates (30). The result of 
5this inhibition affects the rate of viral assembly and can lead to the production of 
defective viral particles that are unable to establish another round of infection (31).
1.3.4 Integrase strand transfer inhibitors (INSTIs)
INSTI enter the cell by passive diffusion or endocytic adsorption. Once in the 
cytoplasm, they can bind to the integrase enzyme, but only access the enzyme’s 
active site once there has been a conformational change that is only induced after 
the enzyme catalyzes the 3’-end processing reaction (32). The 3’-end processing 
reaction exposes a dinucleotide (CA) at the end of the viral cDNA that will even-
tually allow for integration into the host genome via the strand transfer reaction 
(32). To catalyze the strand transfer reaction in the nucleus, Integrase requires 
association with the host factor – lens epithelium-derived growth factor (LEDGF/
p75) (33) and divalent magnesium ions to stabilize its active site. The magnesium 
ions are sequestrated by INSTIs that have a β-diketo acid group as part of their 
chemical structure. The β-diketo acid group in INSTIs has a high binding affinity 
for magnesium ions (34).
1.3.5 Fusion Inhibitors (FIs)
Fusion inhibitor (FI) drugs are delivered subcutaneously and have an extracel-
lular mechanism of action upon entering the systemic system (35). FIs are in the 
form of short synthetic polypeptides (36 amino acids in length) with a short half-
life (less than 4 hours), and specifically, act as structural analogs that bind to the 
heptad region (HR-2) of HIV-1 gp41. HR-2 associates with HR-1 during hairpin 
formation to form the 6-helix bundle that facilitates attachment of the host cell and 
viral membranes (36). Hence, FIs competitively interrupt the hairpin formation 
process that facilitates HIV-1 env gp41 glycoprotein folding, preventing entry of 
the virus (36). 
1.3.6 Inhibitors of co-receptor usage (CCR5 antagonists)
CCR5 antagonists inhibit HIV-1 attachment by preventing the interaction of HIV-1 
gp120 with CCR5 co-receptor used by CCR5 viral strains (R5-tropic) to enter the 
cell. The molecular antagonists bind in a side pocket region of the CCR5 molecule 
and cause a conformational change that disrupts the CCR5’s molecular recogni-
tion of HIV-1 gp120 (37).
1.4 Biological basis and mechanism of drug resistance
HIV-1 has a high mutation rate determined to be 4.1 ± 1.7 x 10-3 per base per cell 
in vivo (38), and this translates to an arbitrary calculation of about 1-36 mutations 
occurring in each RNA genome target per round of replication. This is due to the 
6error-prone HIV-1 RT enzyme that lacks a 3’- 5’ exonucleolytic proofreading (39). 
The error rate of the HIV-1 RT is one of the factors for the basis of HIV drug resist-
ance – that is, the virus acquires mutations that enable it to grow in the presence 
of drugs. Besides, HIV-1 has a high recombination rate when the co-infection of a 
cell occurs with more than one variant (40). The high recombination rate facilitates 
an interchange of HIV genomic sequences one or all of which might harbor drug 
resistance mutations (41). HIV replicates as a pool of diverse viral strains termed 
as quasispecies that differ slightly in their genetic makeup in an individual (42). 
The sequence diversity of HIV has led to its systematical classification into two 
types (HIV-1 and HIV-2); groups (M, N, O, P), subtypes within groups and circu-
lating recombinant forms that may all evolve different mechanisms of acquired 
resistance mutations and reduce the efficacy of ARV therapy (43).
1.5 HIV-1 resistance mechanisms against ARV drugs
HIV-1 drug resistance mutations can be described as primary (major) or second-
ary, which encompasses additional descriptive terms, such as minor and accessory 
or compensatory mutations (40). Most drug resistance mutations occur in the pol 
gene and those that are detected by standard genotypic tests confers resistance to 
4 of the ARV drug classes (NRTIs, NNRTIs, PIs, and INSTIs). These 4 ARV drug 
classes are the main compounds in first and second-line therapy globally. The fol-
lowing section will only describe resistance mechanisms to these drug classes and 
exclude resistance mechanisms to other classes.
1.5.1 Resistance mechanisms to NRTIs
The major resistance mutations for NRTIs can be further classified into primer 
unblocking mutations or discriminatory mutations based on their occurrence near 
the HIV RT active site (40). Primer unblocking mutations, also referred to as thy-
midine analog mutations – TAMs, have an effect on ATP-mediated phosphorolytic 
excision of nucleosides, a process shown to reverse the incorporation of NRTIs 
(44). TAMs occur near the active site of HIV-1 RT enzyme and are selected by 
thymidine analogues AZT and D4T. TAMs occur in two pathways – type I or type 
II. The type I TAMs include M41L, L210W, T215Y show increased high-level 
of resistance to TDF, ABC and ddI, whereas the type II TAMs, which include 
D67N, K70R, T215F, K219Q/E are described for intermediate resistance to AZT 
and D4T(45).
Discriminatory mutations include clinically observed examples, such as K65R and 
M184V. K65R causes intermediate to high resistance to TDF, ddI, ABC, and d4T 
and low and intermediate resistance to 3TC and FTC. M184V causes high-level 
resistance to 3TC and FTC (46). Discriminatory mutations are so named as they 
enable a conformational change in the HIV-1 RT active site to ‘discriminate’ / or 
identify the NRTI from the cell’s native dNTPs (40).
7Minor and accessory or compensatory mutations for NRTIs depend on evolutionary 
selection forces that stem from the host immune system as well as drug pressures. 
The appearances of these mutations are usually assumed to restore viral fitness, 
which in turn, is usually affected when the virus acquires major mutations. One 
example is the A62V mutation that is a non-polymorphic mutation that occurs in 
HIV-1 A subtype and thought to compensate for viral fitness when it occurs with 
K65R (46). However, it was shown that A62V has no effect when it occurs with 
K65R and M184V in HIV-1C (Njenda DT, Master’s Thesis, https://scholar.sun.
ac.za/handle/10019.1/9866).
1.5.2 Resistance mechanisms to NNRTIs
The hydrophobic binding pocket for NNRTIs is formed by the amino acid residues 
L100, K101, K103, V106, T107, V108 V179, Y181, Y188, V189, G190, F227, 
W229, L234, and Y318 and mutations in the nucleotide positions of one of these 
sites can potentially cause resistance to NNRTIs (47). 
K103N and Y181C are the most common mutations known to cause intermediate to 
high-level resistance against first (NVP, EFV) and second (ETR, RPV)-generation 
NNRTIs (46). K103N is an exception as it occurs outside the hydrophobic bind-
ing region. The K103N mechanism of action involves a hydrogen bond induced 
by its presence that prevents entry to the binding pocket region for NNRTIs (48). 
Minor mutations for NNRTIs usually occur from codon 225 to 318 of HIV-RT 
enzyme and usually occur with major mutations and have the impact of reducing 
the susceptibility of NNRTIs (47)
1.5.3 Resistance mechanisms to PIs
Resistance mutations to PIs occur less frequently in the protease gene in clinical 
practice (49). The development of key mutations to reduce the binding ability of 
PIs to the homodimer active site of the protease enzyme occurs near the substrate-
binding cleft of the enzyme (50). These mutations have the effect of stretching 
the cavity of the active site and causing an unstable binding for the inhibitor (51). 
Common mutations that occur in the protease gene include M46L, I50V, D30N, 
G48V, V82A, I84V and L90M that have been shown to have clinically relevant 
HIV-1 drug resistance (52). 
1.5.4 Resistance mechanisms to INSTIs
The catalytic core of the integrase enzyme is stabilized by the geometry of three 
residues termed the ‘DDE’ triad (amino acid residues D64, D116, and E152) (53). 
Resistance mechanisms to INSTIs, develop as a result of conformational changes 
induced by mutations that occur in the catalytic core, such as N155H and QI48H 
that increase the binding energy requirements for INSTIs. Other mutations (G118R, 
8Y143C/R) that have been described may impose steric hindrances to INSTIs 
such as EVG and RAL that have an oxadiazole group within their structure (54). 
Accessory mutations, such as R263K, may play a role in decreasing the viral DNA 
binding or may compensate for viral fitness, such as E138A and G140A (55). Other 
mechanisms of resistance that are currently being explored for INSTIs, such as 
DTG involve mutations in the LTR region (56). It is hypothesized that mutations 
in the LTR region could disrupt conventional integration, leading to linear forms 
of unintegrated viral DNA (possibly containing resistance mutations) that could 
still maintain a basal expression of the viral mRNA, that in turn will lead to viral 
production of INSTI resistant viruses (57). Overall, resistant mutations to INSTIs 
are not well characterized and require more research effort.
1.6 Drug resistance classification
Drug resistance mutations can be classified as pre-treatment drug resistance (also 
called pre-therapy or baseline drug resistance), and it refers to drug resistance 
mutations that are detected before a person starts therapy (2). Drug resistance 
mutations can also be classified as acquired/ therapy-induced resistance (resist-
ance that develops when an individual is receiving ARV therapy over time (58). 
Pre-treatment drug resistance can be observed as possibility of two scenarios. The 
first being pre-treatment drug resistance as a result of a transmitted infectious 
resistant virus from one individual to another – termed as transmitted drug resist-
ance (TDR) (58, 59). TDR can either be horizontal transmission via heterosexual/
homosexual intercourse or be vertical via mother to child transmission (MTCT) 
and may be hard to detect owing to the sensitive limit of standard genotypic assays 
and the possibility of reversion of drug resistance virus to wild- type forms (60). 
The second scenario involves pre-treatment drug resistance as a result of undocu-
mented ARV therapy in individuals who present at the clinic as therapy-naïve 
HIV-1 infected patients. In most cases these individuals are initiated on treatment 
without genotypic testing, which is usually the standard of care in high-income 
countries (HIC), but not routine in LMIC (61). 
1.7 Drug resistance in Sub Saharan Africa
HIV drug resistance remains a challenge for SSA. Figure 3 below presents a map 
of Sub-Saharan Africa as classified by the world bank with median estimates of 
pre-treatment and acquired drug resistance. Pre-treatment and therapy failure-
associated/acquired drug resistance mutations reports published from 2010 to date 
are indicated in tables 3, 4 and 5 below for Northwest, west and Central Africa; 
Northeast and Eastern Africa and Southern Africa, respectively.
9Figure 3. Sub-Saharan Africa median estimates of pre-treatment drug resistance (in red) 
and therapy failure-associated (acquired drug resistance[ADR]) (in blue). Drug resistance 
range values are included in table 2-4 with references from the literature. ND = no data 
available
1.7.1 Northwest, West and Central Africa
The expansion of antiretroviral programs has been a challenge for Sub-Saharan Africa 
countries in the northwest, west, and central region of Africa due to the high cost 
for acquisition of drugs, lack of virological monitoring and inadequate laboratory 
infrastructure (62). The presence of multiple HIV-1 subtypes adds to the  problem 
of performing timeous screening of infected individuals as well as  achieving 
sustained viral suppression due to the different observed efficacies that different 
ARVs have on non-B subtypes (63). A recent report that included 3736 sequences 
from central African countries (Burundi, Cameroon, Chad, Democratic Republic 
of Congo, Equatorial Guinea) and northwest and western African countries (Benin, 
Burkina Faso, Cote d’Ivoire, Senegal and Togo) had no indication of pre-treatment 
drug resistance, but indicated the frequency of acquired major resistance mutations 
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to NNRTIs and NRTIs to range from 5.5–88.9% (64). The previously mentioned 
report, had good concordance with data from the 2LADY- ANRS12169/EDCTP 
clinical trial. The trial had participant patients from Burkina Faso, Cameroon and 
Senegal and reported a 98.7% prevalence of at least one drug resistance mutation 
to first-line therapy (AZT/d4T+3TC + EFV/NVP) and a therapy failure rate of 
about 77%. Therapy failure due to drug resistance in the 2LADY- ANRS12169/
EDCTP clinical trial was about 50 % of the therapy failure cases (65).
Table 2. PDR and ADR rates for northwest, west and central Africa
Country Pre-treatment drug resistance Acquired drug resistance
Benin 15.5% (66) 2.3% (67)
Cape Verde 3.4–12% (68) 10–47.8% (HIV-1); 
17.6% (HIV-2)(68) (69)
Central African Republic 13.9%(70) 26–76% (71, 72)
Gabon Data unavailable Calculated to 23.4% (73)
Ghana 0.01% (74) 41.7% (75)
Equatorial Guinea 3.2–16.1% (76, 77) 12.7% (78)
Mali 7.9–25.8% (79, 80) 11–92% (81-83)
Mauritania Data unavailable 72.3% (84) 
Niger 6.5% (75) 73% (85)
Nigeria <5–15.9% (86, 87) 1.6–93.8% (88-92) 
Sierra Leone Data unavailable Data unavailable
Togo 26.8% (93) 18.1–51.6% (94)
Gambia Data Unavailable Data unavailable
Guinea-Bissau Data Unavailable 60%(95) 
Liberia 5.9% (96) 63–71% (97)
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1.7.2 Northeast and Eastern Africa
Table 3. PDR and ADR rates for the northeast and eastern Africa
Country Pre-treatment drug resistance Acquired drug resistance
Kenya 1.1–10.93% (98–102) 7–68% (103–105)
Ethiopia 6.5–40% (106, 107) 81.8–86.7% (108, 109)
Eritrea Data unavailable Data unavailable
Somalia Data unavailable Data unavailable
Uganda 1.4–41 % (110-117) 93.8–100% (118–120)
Sudan Data unavailable Data unavailable
South Sudan Data unavailable Data unavailable
Rwanda 3.5–3.6 % (121) 9.1–95 % (122–124) 
1.7.3 Southern Africa
Table 4. PDR and ADR rates for southern Africa
Country Pre-treatment drug resistance Therapy failure associated resistance
South Africa 4.6–9% (125-127) 52% (128)
Lesotho Data unavailable Data unavailable
Swaziland 9.1–41.9% (111) Data unavailable
Mozambique 5.4–60.7% (111, 129) 10.1–93% (130–132)
Zimbabwe 23.9–74.7% (111) 6–30.6% (133, 134)
Botswana 3.5–5% (135, 136) 6.6–9.6% (136)
Namibia 7% (137) 5% (137)
Zambia 3-40.2% (138–140) 5–88% (141) 
Angola 1.6–16.3% (142, 143) Data unavailable
Malawi <5–13.3% (144, 145) 20.3–40% (129, 146, 147)
Tanzania 2.2–82.9% (148–151) 34–90% (152–154)
Madagascar Data unavailable 13.9% (155)
Mauritius Data unavailable Data unavailable
Comoros Data unavailable Data unavailable
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1.7.4 Additional challenge for SSA to the success of ART therapy
The projected success of ARV therapy is envisioned under the UNAIDS 90-90-90 
goals (156). However, there are a few additional problems that challenge the overall 
success of ART for Sub-Saharan Africa, and these include drug-drug interactions, 
adherence, limited development of research infrastructure and health care delivery 
systems, and increasing prevalence of diverse HIV-1 subtypes. These are briefly 
mentioned below:
1.7.6.1 Drug-Drug Interactions (DDI)
The treatment of opportunistic infections from bacteria and other viruses in HIV-1 
infected patients compromises the effectiveness of ARV therapy via drug-drug 
interactions and this may lead to the emergence of drug resistance (157, 158). 
This is particularly common in the Sub-Saharan region, where there are high preva-
lence rates of tuberculosis (TB), malaria, hepatitis and fungal infections (159). 
An example is the simultaneous administration of TB drugs (rifampicin – RMP, 
isoniazid – INH, pyrazinamide – PZA, ofloxacin, levofloxacin and moxifloxacin) 
with ARVs (160). Studies have shown that rifampicin is a potent inducer of CYP2B6 
and CYP3A4 liver enzymes and its co-administration with ARVs, such as NVP 
and ATV, leads to a reduction in the plasma levels of the ARV drug (161, 162)
1.7.6.2 Adherence
Lack of drug stocks, ARV-related toxicities leading to adverse reactions and poverty 
characterize some of the problems that lead to non-adherence in HIV-1 infected 
patients in Sub-Saharan Africa (163). Access to ARVs from remote locations also 
plays a factor and studies have shown a relationship between the distances to near-
by healthcare facilities from an HIV infected patient’s residence relates to their 
probability to a loss- to- follow-up (LTFU) impacting their ability to access ARVs 
(164). None and sub-optimal adherence lead to the evolution of drug resistance 
and faster rates of progression towards virological failure (165). Other factors 
include influences of traditional medicine, faith-based healing, alcohol abuse and 
poverty (166) (which often leads to depression and food insecurity) are described 
in a meta-analysis study (167) as ‘bottlenecks’ for achieving high adherence in 
HIV-1 infected patients.
1.7.6.3 Limited infrastructure development
The development of viral load monitoring and genotypic resistance testing facili-
ties is crucial for the success of early initiation of ARV therapy (168). However, 
most Sub-Saharan African countries are lagging in this endeavor. Given that there 
is an increasing level of HIV-1 diverse types that require efficient and timeous 
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detection of new HIV infections, the success and implementation of national ARV 
programs will largely rely on coordinated efforts of government support and expert 
contribution from healthcare providers (169).
1.8 HIV-1 prevalence and drug resistance in South Africa
South Africa has the largest antiretroviral program in the world. About 4.4  million 
individuals are receiving treatment and only 47% have achieved viral suppression 
below the detection limit as determined by clinical assays (170). HIV-1 subtype C 
is the dominating strain, but more and more circulating recombinant forms are 
emerging (171). HIV prevalence rate in South Africa remains one of the highest in 
the world and is approximately 19% for adults aged 15-49 nationally, with some 
remarkable differences between individual provinces in South Africa (Figure 4) 
(172).
Figure 4. HIV-1 prevalence by the province in South Africa (172)
Pre-treatment drug resistance (PDR) has increased since the country’s national 
ARV rollout program in 2004 and this increase, is specifically evident in HIV 
pregnant women receiving NNRTIs or a combination of NNRTIs and NRTIs (173).
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The hardest-hit provinces in South Africa when it comes to PDR are Gauteng 
(162) and Eastern Cape (174), followed by Mpumalanga (175) and KwaZulu 
Natal (173) and lastly by Limpopo (176), Western Cape (127) and the Free State 
(177) (Figure 5).
Figure 5. HIV-1 PDR percentage rates by province in South Africa. NA = no data found/
available
Projections for South Africa for HIV-1 infected patients requiring second-line 
protease inhibitor (PI)-based boosted treatment will increase to over 900000 by 
the year 2030 from the current estimate of about 128000 individuals that are now 
on PI-based therapy (178). The major challenge for managing HIV-1 patients on 
PI-based treatment is to make determinations for therapy failure, considering that 
major protease-resistant mutations are rarely present at treatment failure (179).
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1.9 HIV-1 prevalence and drug resistance in Sweden
The HIV-1 burden in Sweden has reduced drastically since the introduction of 
combination therapy, and Sweden is the first country to reach the UNAIDS/WHO 
90-90-90 goals (180). With a prevalence of less than 0.2%, Sweden is mainly domi-
nated by HIV-1 Subtype B, though there is evidence that circulating  recombinant 
forms are emerging and are being driven by specific transmission clusters (181). 
The central transmission cluster is with Men who have sex with other men (MSM) 
that are estimated to be around 100000 in Sweden (182).
The prevalence of HIV-1 drug resistance in Sweden remains low, but shows a 
 significant increasing trend from less than 1.1% (183) to about 7.1 % with the 
majority of resistant carriers believed to be immigrants coming from SSA and MSM 
clusters (184). The majority of HIV-1 drug resistance is reported for patients who 
are using NRTI and NNRTI -based regimens and using ultra-sensitive genotypic 
resistance methods (107). This has led to recommendations for HIV-1 patients who 
have immigrated to Sweden, particularly from SSA to be initiated on PI-based 
regimen (184). However, the risk of virologic failure has been shown to be high 
in HIV non-B subtypes (185) and recommendations to initiate patients on PI regi-
mens will still require close monitoring and frequent genotypic resistance testing 
in suspected cases of failure. 
Overall, HIV-1 research in Sweden still has a significant role and is required to 
understand the dynamics of transmission of non-B HIV-1 subtypes as well as 
mechanisms of drug resistance that could ultimately change the HIV-1 Swedish 
epidemic in the foreseeable future.
The next chapter will focus on the specific role of gag and protease in affecting 
the development of HIV-1 resistance to ARV drugs.
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2 ROLE OF GAG AND PROTEASE IN DRUG 
RESISTANCE
2.1 HIV-1 Group Antigen protein (Gag)
HIV-1 gag is a structural gene whose precursor (designated as gag Pr55Gag) has a 
molecular weight of 55kDa and is cleaved into mature proteins – Matrix (MA), 
Capsid (CA), nucleocapsid proteins (NC), p6 and spacer proteins p1 and p7 by 
the viral protease encoded by HIV-1 pol gene (186). The Gag precursor is thought 
to have assembly and membrane targeting functions, whereas the mature proteins 
are involved in uncoating and disassembly (186). There are approximately 2000 
copies of Gag in a single HIV-1 virus particle (187) that comprises about 50% of 
the viral mass (188). 
HIV-1 resistance mechanisms to PIs have been proposed to include the develop-
ment of mutations in the gag gene at protease cleavage sites (189). In total, there 
are 12 protease cleavage sites within the HIV genome, and 5 of them are in the 
gag gene (190, 191). Gag mutations at cleavage sites are hypothesized to cause 
an interaction with the active site of protease reducing the binding affinity of PIs 
and thereby allowing the enzyme to resume its proteolytic function (192-194). 
Gag cleavage site mutations reported include V128I (MA/CA); S373P,I376V 
(p2/NC); A431V and K436R (NC/p1) and P453A(p1/p6)(195) and are thought 
to increase PI resistance when occurring with primary drug resistance mutations 
in protease (189).
Another mechanism involves the development of gag mutations that act as secon-
dary or compensatory mutations and restore viral fitness (189). One example of 
compensatory gag mutations, is a study involving the PI darunavir (DRV), the 
observation of gag mutations H219Q and I223V appeared to compensate for viral 
fitness in the presence of primary protease mutations (196). Other studies had shown 
that there is a minimal association of gag cleavage site mutations with primary 
resistance mutations and that gag non-cleavage mutations play a role (197). The 
most common gag non-cleavage site mutations characterized (mainly in the MA 
and CA regions) include T242N/S(198); T427D/N, E46V/K, Q369L(199); R76K, 
Y79F, and T81A(200). In a recent longitudinal study involving four patients from 
Spain who had been treated with PIs for nine years, the co-evolution of MA and 
CA non-cleavage site mutations was strongly associated with protease mutations 
(201) implying the role these mutations may have in impacting PI-based therapy.
In addition to the MA and CA regions, the C-terminal of gag involving the p6 
has also been implicated in conferring resistance to ARVs in a similar mechanism 
that restores viral fitness. One example, is a study that examined the association 
of gag p6 mutations P5L/T and K27Q/N in enhancing p6 function in  packaging 
pol molecules and reducing the potency of NRTI-based therapy against HIV 
CRF02_AG and subtype G (202). Further evidence of the role of gag p6 in resist-
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ance and restoration of viral fitness is provided by studies that found amino acid 
motif duplications and insertions in the p6 gene. 
The most common of these motifs in p6 that provide an escape mechanism for increased 
incorporation of RT molecules include PTAPP duplications (203, 204). More recent 
studies have described a PYxE insertion in gag p6 of HIV-1 subtype C that enhances 
viral replication and is associated with PI-based treatment failure (205, 206).
Overall, much remains unknown about cleavage, non-cleavage and c-terminal 
mutations in gag and the role they play. However, there is a strong link between 
gag and protease mutations, and this is particularly important as PIs are still used in 
the clinical setting and hence understanding patterns and mechanisms of  resistance 
to PIs is crucial to ensure the management of HIV-1 patients.
2.2 HIV-1 protease
HIV-1 Protease is a homodimeric aspartic enzyme with a molecular weight of 
21.6kDa that catalyzes the cleavage of Gag and Gag-Pol polyproteins (207). 
The catalytic site of the HIV-1 protease interacts with the protease inhibitor (PI). 
Mutations in the active site that lead to protease resistance against PIs are desig-
nated to be primary mutations, whereas those outside are termed to be secondary 
mutations (208). Primary mutations decrease the proteolytic function of protease 
reducing the replication capacity of the virus. Primary protease muations are affected 
by amino acid residues 25-32, 47-53 and 80-84 of Protease (209). Secondary or 
minor mutations can be pre-existing as naturally occurring polymorphisms (NOPs) 
or can develop after primary mutations have appeared in the presence of PI treat-
ment (208). Most studies on the development of PI resistance have observed that 
secondary mutations have a compensatory effect on the fitness of protease instead 
of conferring resistance directly and occur with a frequency range of 40-45% for 
the entire Protease amino acid sequence (209). One example is a mutagenesis study 
the reported the impact of secondary mutations M36I and A71V when co-occurring 
with the primary mutation D30N to have more than 10-fold increase in resistance 
against the PI drugs nelfinavir and ritonavir (210). 
Finally, it’s unclear why specific mutations impact Protease extensively in some 
HIV-1 subtypes and not in others. For instance, the mutation L90M in combination 
with D30N and N88D had a more significant impact on increasing resistance to PI 
drugs in HIV-1C compared to HIV-1B (211). One explanation for this is that the 
plasticity of HIV-1 Protease allows for various permutations of mutations in both 
the primary and secondary sites to have an impact on the conformation of the active 
site and its hydrophobic interactions with the inhibitor (209). How this interaction 
differs amongst HIV -1 subtypes is a question yet to be fully answered.
The next chapter will look at some newer drugs that have the potential for use as 
long-acting drugs and alternatives to PIs for treatment in HIV-1 non-B subtypes.
18
3 NEWER ANTIRETROVIRAL DRUGS
3.1 EFdA
EFdA (4’-Ethynyl-2’-Fluoro-2’ deoxyadenosine) also known as MK-8591/Islatravir 
is a result of a modification of one of 4’-ethynyl compounds described initially 
to act as NRTIs and shown to have potent activity against HIV-1, drug-resistant 
strains of HIV-1 (212) and more recently HIV-2 (213). Structurally, EFdA is dis-
tinct from other classical NRTIs in that it retains a 3-OH group in its ribose sugar 
and has an ethynyl and fluoro group (214). Chemical synthesis of EFdA has been 
improved over time from a yield of 2.5% to 37% (215). Currently, using less costly 
starting material and fewer purification steps, EFdA synthesis has an overall yield 
of 90% (216), allowing mass production of the drug form clinical applications.
Recent studies have confirmed that EFdA has multiple modes of HIV-1 inhibition 
and has been termed to be a translocation-defective reverse transcriptase inhibi-
tor (TDRTI) based on one of its mode of inhibition. The first mode of inhibition 
involves the triphosphate form of EFdA (EFdA-TP) acting as a direct chain ter-
minator, whereas the second mode involves EFdA-TP acting as a delayed chain 
terminator in a template sequence-dependent manner (217). The third mechanism 
of inhibition involves its monophosphate form (EFdA-MP) being incorporated in 
the primer used by HIV RT for the extension. The insertion of the monophosphate 
form in the primer leads to a mismatch that makes it hard for HIV RT to copy the 
template and to excise the monophosphate form of EFdA (217). As an attractive 
candidate ARV drug for clinical application, EFdA has been shown to have low 
toxicity and high resistance to deamination by adenosine deaminase (increasing its 
intracellular half-life(~17.5 to >72h)) – a characteristic that enhances its antiviral 
activity significantly more than other NRTIs (214). In vitro studies looking at the 
intestinal absorption and permeability of EFdA have shown that the drug mainly 
uses the paracellular route (characterized by compact spaces between cells and 
primarily used by small molecules for passive diffusion) (218). In vivo, EFdA 
has been shown to have efficacy in the gastrointestinal and female reproductive 
tracts of humanized bone marrow, liver and thymus mice (219). Additionally, it 
was also shown in rhesus macaques that EFdA had strong antiviral activity against 
simian immunodeficiency virus (SIV) for extended periods at sub-nanomolar 
concentrations (220).
EFdA has already entered human clinical trials. Phase I clinical trial evaluating 
the dosing and safety profiles of EFdA concluded that EFdA did not result in any 
adverse effects and could be tolerated even when administered up to 30mg per 
day (221). Phase II studies are being conducted as of the time of this writing. It 
is worth noting that the systematical evaluation of EFdA in comparison to NRTIs 
and NNRTIs has not been fully explored.
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3.2 Bictegravir
WHO has recently advocated for the use of INSTIs as part of first-line therapy in 
low- and middle-income countries (2). It is worth noting that INSTI-based-regimens 
have been shown to have the same efficacy with PI-based regimens (222). 
Bictegravir (BIC), a new INSTI drug was developed as a result of limitations 
observed with first-generation INSTI drugs Raltegravir (RAL) and Elvitegravir 
(EVG). These limitations include a low genetic barrier to resistance for all first-
generation INSTIs, the requirement for twice-daily dosing specifically for RAL 
and the need for pharmacokinetic enhancement for EVG (223, 224). Problems 
with the second generation INSTI drug – Dolutegravir (DTG), that included drug-
drug interactions, increase in patient serum creatine levels (223) and neural-tube 
defects in neonates (225) also encouraged the development of BIC. Structurally 
BIC has different substituted groups in its benzyl tail and a cross-linked bicyclic 
ring that reduces its chances to activate the pregnane X receptor (PXR) and  lowers 
the risk of drug-drug interactions (224).
The mechanism of action of BIC involves blocking the active site of HIV-1 Integrase, 
consequently impairing its stand-transfer ability, but BIC acts as a weak inhibitor for 
the 3’ processing activity (224). In vitro studies have reported BIC to have a longer 
half-life of dissociation from Integrase/DNA complexes compared to RAL, EVG 
and DTG (226). In clinical studies, the safety profile for BIC has been evaluated 
in a 10-day phase Ib study and it was shown that BIC was tolerated when doses of 
up to 100mg per day were administered and no INSTI associated mutations were 
observed (227). However, in a 24-week phase II study which compared the fixed-
dose combination of BIC with FTC and TAF against DTG, FTC and TAF, reported 
an interesting observation on the long-term potential adverse effects of using BIC 
Though perhaps not statistically relevant one patient in the 24-week clinical trial 
taking BIC, FTC and TAF developed urticaria (228). However, HIV-1 prevalence 
and transmission resistance studies reported no clinical resistance development for 
BIC and have advocated for no baseline resistance testing for patients initiating 
BIC regimen as first-line therapy (229). Phase III clinical study of BIC containing 
regimen compared to DTG containing regimen indicated that BIC was not infe-
rior to DTG and that it was equally tolerated with no adverse effects significantly 
related to its use (230). To date, HIV-1 subtype-specific differences for BIC have 
not been evaluated extensively.
3.3 Cabotegravir
Cabotegravir (CAB) (also known as GSK1265744) is an INSTI drug with the 
same mechanism of action as DTG and BIC. CAB is mainly degraded by uridine 
diphosphate glucuronosyltransferase (UGT) 1A1 and has an approximate half-life 
of 40 days (231). 
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The crystalline form of CAB has been used to develop the long-acting form that is 
administered subcutaneously as nanosuspension particles of the drug (231). An in 
vitro study assessed the potency of CAB against five different subtypes of HIV-1 
derived from treatment-naive patients and reported a mean EC50 of 0.91nM (232). 
To add on, the previously mentioned study indicated that CAB had high EC50 and 
EC90 values to RAL-resistant viruses that contained G140S and Q148H integrase 
mutations. In contrast, it was shown in another study (233) that CAB had a lower 
EC50 compared RAL and EVG for G140S and Q148H-carrying viruses. On the 
other hand, an in vivo animal study showed that CAB long-acting administered 
prophylactically, protected macaques from SIV infection (234). Although a dif-
ferent study emphasized caution and pre-therapy testing before CAB is given as 
prophylaxis as in the study’s SIV animal model, some macaques developed resist-
ance to CAB and could not protect against viral infection (235).
Phase I clinical trials demonstrated that up to 30 mg of CAB could be tolerated 
with no adverse effects (236) and a supratherapeutic dose of up to 150mg every 12 
hours given to healthy individuals, did not affect the cardiovascular system (237). 
Other phase 1 studies, have shown CAB had no adverse effect on the liver (238) 
and kidney function (239). A Phase II study reporting tolerability and pharmaco-
kinetics of injectable CAB had a significant number of patients discontinuing 
treatment due to injection site reactions (ISR) (240). In the LATTE-2 phase II 
study, CAB was paired with RPV and proved to be as effective as EFV combined 
with two NRTIs (241, 242).
Regardless of support data, from clinical studies on the safety, tolerability, favora-
ble pharmacokinetics, and antiviral efficacy of CAB, more research is required to 
understand the resistance mutations that can develop as a result of continued use of 
CAB. This will be crucial in situations where CAB long-acting-based treatment is 
given with other drugs treating co-infections as it is predicted that it might cause 
drug-drug interactions (243).
I will now present my findings for my thesis in the next chapter.
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4 PRESENT FINDINGS
4.1 Thesis aims and objectives
ARV drug development and the majority of clinical trials has mainly been based 
on using HIV-1 subtype B (HIV-1B) infected patients. The majority of these 
patients are from high-income countries (HIC). The genetic and replicative capacity 
 differences among subtypes can lead to the emergence of subtype-specific resist-
ance mutations, which frequently also alter viral fitness (244-246). Substantial 
evidence supports the impact of genetic diversity on ART responses and drug-
resistance pathways (247-249).
I hypothesized that HIV-1 subtype-specific differences can impact the susceptibil-
ity towards antiretroviral drugs that can affect the treatment efficacy and alter the 
drug resistant mutations pathways in non-B HIV-1 subtypes significantly. 
The overall aim of my thesis is to investigate the potency and drug resistance sus-
ceptibility profile of clinically relevant old and new ARV drugs that can potentially 
be used as second-line therapy in non-B dominating countries. The specific aims 
include the following:
1. To understand the ex vivo potential of HIV-1C and non-C subtypes against PIs 
and type the prevalence of ADR in patients failing bPI-based therapy that is 
second-line treatment regimen in South Africa (Paper I). 
2. To understand the role of PYxE-mutations that was identified by Neogi et al. 
(206) in viral-fitness and drug susceptibility. The PYxE (where x represents 
a lysine [K], a glutamine [Q] or an arginine [R]), occurs naturally in HIV-1C 
viruses from Eastern Africa (Ethiopia and Eretria) but occurs more in HIV-1C 
infections from India and South Africa (Paper II). 
3. To investigate the virological and biochemical inhibitory potentials of a 
new reverse transcriptase inhibitor 4’-Ethnyl-2’-fluoro-2’-deoxyadenosine 
(EFdA) against broad-spectrum HIV-1 chimeric viruses of different subtypes 
(Paper III).
4. To understand the ex vivo antiretroviral potency of the newer INSTIs 
Cabotegravir and Bictegravir in non-B HIV-1 subtypes (Paper IV).
The studies aim to understand the potential subtype-specific differences in viral 
fitness and drug susceptibility against the drugs that target different stages of viral 
replication that includes, protease-mediated cleavage and maturation (Paper I 
and II), reverse transcription (Paper III) and integration (Paper IV) (Figure 6).
22
Figure 6. Thesis overview
4.2 Materials and methods (Papers I, II, III and IV)
4.2.1 Ethical considerations 
Ethical clearance was granted by the Stellenbosch University Human research 
and ethics committee (HREC) under Ethics No. N15/08/71 for patient sequences 
used in Paper I. For Paper II, III and IV ethical clearance was granted by the 
Stockholm Regional Ethics Committee. The ethical permits were designated under 
the following numbers: 2005/1167-31/3 and 2014/928-31/2 for Paper-II; 2014/928-
31/2 and 2013/1944-31/4 for Paper III; and 2006/1367-31/4 and 2014/928-31/2 
for Paper IV. 
4.2.2 Bioinformatics and statistical analysis
The goal of Paper I was to understand the acquired HIV-1 resistance patterns and 
prevalence in an HIV-1 pandemic dominated by HIV-1 subtype C. To this regard, 
data from the drug resistance Tygerberg (DRT) cohort containing HIV-1 gag and 
protease sequences of patients who had failed first-line and second-line treatment, 
were assessed for the prevalence of acquired drug resistance mutations (using the 
algorithms from version 8.8 of the HIV Stanford database(46)) and subtype (using 
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COMET HIV-1 subtype tool (250)). In Paper II, III, and IV, non- parametric 
statistical analysis was performed for drug sensitivity and viral growth kinetics 
assays using GraphPad Prism v6 and 8 (GraphPad Inc. La Jolla, USA).
4.2.3 RNA extraction and synthesis of recombinant viruses
Recombinant viruses (n=24) that were used in all papers, were derived from patient 
samples obtained from the Swedish InfCare cohort that includes patients who have 
migrated from other Sub-Saharan African countries (inclusive of South Africa) 
and Asia. Briefly, the recombinant viruses were derived by amplifying the gag-
pol region using a previously described PCR protocol (251) and cloned into the 
pNL4.3 infectious vector backbone using BssHII and SalI restriction sites (Figure 7).
Figure 7. Schematic of recombinant plasmids used in all papers presented in the thesis. 
Image generated using Snapgene software (SnapGene software from GSL Biotech;  available 
at https://www.snapgene.com/)
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4.2.4 Sanger sequencing and analysis
Patient amplicons spanning the gag-pol of recombinant viruses from the Swedish 
cohort were sequenced using published primers as previously described (251). 
Sequence fragments were assembled using BioEdit sequence alignment editor 
(252), and phylogenetic analysis was done using Mega X (253). 
4.2.5 Cell culture and reagents 
For Papers, I, II, III and IV, recombinant plasmids were transfected in HEK293T 
cells to generate viral stocks. HEK293T cells were propagated in 10% fecal calf 
serum Dulbecco’s modified Eagle medium (DMEM, Sigma, USA) supplemented 
media. TZM-bl reporter cells were also propagated and maintained with the cell 
culture media mentioned above. The TZM-bl reporter cell line is derived from 
HeLa cells and stably expresses high levels of CD4, CXCR4 and CCR5. In addi-
tion, the TZM-bl cell line has integrated copies of the luciferase gene under the 
control of the HIV-1 promoter gene that enables the indirect quantification of 
HIV-1 infection when the HIV-1 promoter is activated. To add on, a panel of 
NRTI and NNRTI-resistant viruses were obtained from the National Institutes of 
Health (AIDS reagent program, NIH, USA) and used in viral infectivity and drug 
sensitivity assays.
4.2.6 Viral Infectivity and drug sensitivity assay (DSA)
The following ARV drugs were purchased from Selleckchem, USA: for drugs 
used in the Paper I and II: ATV, DRV, and LPV; for Paper III: NVP, EFV, ETR, 
RPV and TAF. EFdA used in Paper III was provided by Professor Stefanos G. 
Sarafianos. For Paper IV, BIC and CAB were provided by ViiV Healthcare/GSK 
(Research) Triangle Park, North Carolina, USA) and Gilead Sciences (Foster 
City, California, USA), respectively. RAL, EVG, and DTG were purchased from 
Selleckchem, USA. The DSA was performed by determining the extent to which 
the antiretroviral drugs inhibited the replication of the reference virus (pNL4.3) 
and gag-pol derived recombinant viruses. The DSA was performed by having three 
technical replicates (triplicate) for each virus added on a 96-well cell culture plate. 
Each triplicate was added at a specified concentration within the dynamic range of 
the drug for the assay before the assay plate was incubated at 37˚C for 48 hours. 
End-point detection of the plate was done using Bright glo™ Luciferase assay kit 
(Promega, USA). The output at endpoint detection is relative light units (RLU) and 
is proportional to infectious virions produced in the DSA.The drug concentrations 
required for inhibiting virus replication by 50% (EC50) is then calculated using 
the RLUs by a dose-response curve plotted using non-linear regression analysis 
in GraphPad Prism, version 6.07 (GraphPad Software, USA). The DSA described 
in all papers was performed at least three times and the output for the drug EC50 
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results was used to compute the fold change value (FCV) for each virus relative 
to pNL4-3. PI DSA requires two rounds of infection in TZM-bl cells in contrast 
to RTI and INSTI drugs as shown in Figure 8.
Figure 8. Schematic representation of drug sensitivity assay (DSA).
4.2.7 Viral growth kinetics assays (VGK) 
Viral growth kinetic assay performed in Paper II was done using MT4-cells and 
the amount of p24 from supernatants collected on days 0, 3, 5- and 7-days post-
infection was used as the end-point to calculate viral fitness relative to control 
reference virus, pNL4-3. Viral fitness was calculated using the formula described 
by Koval et al. (254) and graphical representation of the result was made using 
GraphPad Prism v6 (GraphPad Inc., La Jolla, CA, USA).
4.3 Results (Papers I, II, III and IV)
4.3.1  Paper I and II
In the Paper I, the prevalence of acquired drug resistance from 2006 to 2014 for 
South Africa for patients failing on protease inhibitor (PI) – based therapy and the 
phenotypic in vitro response to lopinavir (LPV), atazanavir (ATV) and darunavir 
(DRV) was evaluated. This was an additional analysis of an earlier study reported 
for South Africa (255). 1043 sequences from patients mainly failing on LPV/r-
based therapy were analyzed for DRMs. The prevalence of PI mutations during 
the period was around 9%. While primary resistance mutations were detected for 
each class, the most frequent mutations were for PI – M46I, 154V, and V82A; for 
NRTI – M184V and for NNRTI – V106M, K103N, G190A and E138A (Figure 9). 
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Figure 9. Prevalence of ADR muations from PI-based therapy failure patients from 
South African
The PI phenotypic DSA included HIV-1C derived chimeric viruses (n=13) com-
pared to non-C (B =5 and A-like = 4 viruses; total n= 9) viruses representing 
patient samples from the Swedish InfCare database. Among the HIV-1C strains 
62% (8/13) were from patients got infected in SSA including counties South Africa, 
Burundi, Ethiopia, Somalia and Kenya) The samples from the Swedish InfCare 
have diverse country origins and the phylogenetic relationship of the viruses is 
indicated in Figure 10. 
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Figure 10. Chimeric viruses used for PI DSA study. The prefix (SE =Sweden) indicates the 
origin of the recombinant virus and in bracket self-reported country of infection
Phenotypic drug sensitivity results obtained in Paper I indicated that there were 
no subtype-specific differences found in HIV-1C and non-C viruses for LPV 
(p=0.948), ATV (p =0.067) and DRV (p=0.651). However, some HIV-1C viruses 
indicated a reduced response to all PI drugs (Figure 11). HIV drug resistance 
and sequence summary for chemeric viruses used in the PI DSA using HIV drug 
resistance algorithms from the Stanford HIV Database indicated no major and 
accessory mutations except for two HIV-1C viruses that have accessory PI muta-
tions (K20T, G73C).
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Figure 11. Heat-map for chimeric viruses used in the Paper I showing DSA profile of 
LPV, ATV and DRV
Given that chimeric viruses used in the Paper I was derived from  treatment-naive 
patients whose viral protease gene did not contain major and accessory mutations 
it was reasonable to hypothesize that HIV-1 gag could influence the response to 
PI drugs. Hence, in Paper II, the gag gene was investigated, 
In Paper II, the gag-p6 region in HIV-1C recombinant viruses was investigated 
to assess its impact on viral fitness. The gag-p6 late domain region of gag inter-
acts with the host cell protein ALG-2-interacting protein X (ALIX) to facilitate 
active transport of gag to the internal surface of the cell membrane during HIV 
viral assembly and budding (17). 
It was previously shown that HIV-1C has a unique PYxE (x being Arginine (R) or 
lysine (K) or glutamine (Q) amino acid residue) motif insertion in its gag-p6 gene 
where the YPxnL motif has been naturally deleted in HIV-1C viruses and that the 
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PYxE motif is associated with a reduction in PI-based therapeutic response in some 
HIV-1C infected patients (206). In Paper II, the prevalence of PYKE in patient viral 
sequences from three HIV-1 cohorts (Swedish, German and Ethiopian) was higher 
than PYQE (~2 fold). In addition, clinical data from the Swedish cohort looking into 
patients specifically infected with HIV-1C revealed that the viral load and the CD4+ 
T-cell count were higher and lower respectively, in patients carrying PYxE viruses 
compared to the wild-type (WT) HIV-1C. In silico simulation and co-localization 
experiments performed in Paper II aimed to previse and show the interaction of 
ALIX and gag (PYxE). The interaction with ALIX was especially enhanced with 
the presence of the PYxE motif compared to HIV-1C WT. Furthermore, in Paper II, 
it was shown that there is a high binding affinity between ALIX and gag (PYxE), 
and this affinity correlated well with the observed increased replication capacity of 
recombinant HIV-1C containing the PYxE motif when compared with non-C viruses. 
More specifically, viral growth differences were noted for HIV-1C viruses with 
PYKE, PYQE, no PYxE (i.e. WT) and when compared with the reference HIV-1B 
WT. Chimeric viruses with PTAPP duplication (PTAPPd) were also included in the 
assessment as this had been previously shown to impact fitness (256). The order 
of increased fitness was WT HIV-1B > PYKE > PYQE > PTAPPd> HIV-1C WT. 
In addition, the drug sensitivity profile of HIV-1C viruses containing PYKE and 
PYQE had reduced susceptibility to LPV. One of the PYKE viruses also displayed 
reduced sensitivity to TAF. All the viruses displayed high to medium susceptibility 
to NNRTIs and INSTIs tested (EC50 fold change <2). 
4.3.2 Paper III
The results obtained in Paper I and Paper II indicated that HIV-1 subtype-specific 
differences could play a role in influencing ARV drug susceptibility. Hence the 
goal of Paper III was to understand and describe any HIV-1 subtype-specific dif-
ferences to the response of clinically approved and newer ARV drugs. The specific 
aim investigated the ex vivo potency of the novel drug EFdA in comparison with 
first and second-generation NNRTIs – NVP, EFV and ETR, RPV respectively. 
In addition, TAF was also included as an approximate comparator of the same 
class to EFdA. The results obtained indicated that EFdA had a superior ex vivo 
potency compared to all other drugs used in the study in inhibiting all the recom-
binant viruses (n=24) tested independent of HIV-1 subtype. EFdA also inhibited 
RTI resistant viruses (n=9) better than TAF. Independent subtype inhibition of 
EFdA, was also confirmed by steady-state kinetic experiments that showed no 
difference in the incorporation efficiency of different phosphorylated forms of 
EFdA by different HIV-1 reverse transcriptase (RT) subtypes (01_AE, 02_AG, C 
and B). HIV-1 subtype representation for recombinant viruses used in DSA experi-
ments included HIV-1B (n=6),) and HIV-1 A-like (02AG, 01_AE and A1 (n=4)) 
and HIV-1C (n=14). However, DSA data showed HIV-1C to have a significantly 
reduced susceptibility to RPV and ETR (p = 0.017 and p= 0.004 respectively). 
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The in vitro DSA data correlated well with the biochemical experiments performed 
in the study. More specifically, biochemical data was able to demonstrate molecular 
differences of the inhibitory potential of NNRTI drugs mentioned above, against 
different HIV-1 RT subtypes. HIV-1C RT was also shown to have reduced suscep-
tibility to ETR and RPV compared to other HIV-1 non-C subtype RTs.
4.3.3 Paper IV
The observation of subtype-specific differences in Paper III with the use of drugs 
from the RTI class made it rational to continue the investigation of subtype-
specific differences in the INSTI class. This was the primary goal of Paper IV. 
Recombinant viruses (n=24) described in Paper III were used to investigate the 
in vitro drug sensitivity of first (RAL, EVG) and second-generation (DTG, CAB, 
BIC) INSTI drugs. The DSA results obtained indicated that second-generation 
INSTIs have a subtype-independent in vitro potency except for DTG, which indi-
cated to be more potent in non-B compared to HIV-1B subtypes. To add on, DTG, 
BIC, and CAB performed well in inhibiting A-like viruses compared to HIV-1C 
and B Subtypes. However, HIV-1C and HIV 02_AG had a significantly reduced 
susceptibility against first-generation drug EVG (p<0.05). RAL displayed the 
least potency against all subtypes tested. DSA data also compared very well with 
integrase strand-transfer activity biochemical experiments.
The secondary goal in Paper IV investigated the pattern of INSTI primary and 
acquired drug resistance mutations. To this regard, INSTI naïve (n=270) integrase 
sequences [representing HIV subtypes B (n=92), 01_AE (n=25), C (n=82), A1/A2 
(n=22), CRFs (n=21), 02_AG (n=15) and other pure subtypes (n=13)] and INSTI 
experienced (n=96) individuals from a patient-cohort (collected from Swedish 
InfCare) were analyzed. Results in INSTI naïve patients indicated the frequency 
of INSTI primary mutations to be <1% (1/270) and INSTI accessory mutations 
to be 6.3% (17/270). In addition, the M50I polymorphic mutation was observed 
in 18% (49/270) of INSTI naïve patients. However, a prevalence of 24% (23/96) 
primary INSTI mutations was observed in INSTI-experienced patients. The most 
common mutations observed were N155H, Y143G/R, T66S, E92Q, Q148R, S147G, 
E138K, G140A/S. Lastly, there was no observable difference between non-B and 
HIV-1B subtypes in the occurrence of drug-resistant mutations.
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5 DISCUSSION
HIV-1 continues to be a burden in low- and middle-income countries (LMIC) that 
are mainly infected with non-B HIV-1 subtypes. Regardless of the scaling-up of 
ARV rollout programs, efforts to contain the pandemic through early detection and 
virological monitoring of infected patients have not stopped the trend in increasing 
acquired drug resistance (ADR) (2, 257). The combined results of Paper I, II, III, 
IV make a persuasive argument to support the hypothesis proposed in this thesis 
that subtype-specific differences impact the outcomes of ARV therapy and that the 
impact is mainly detrimental to individuals infected with HIV-1 non-B subtypes. 
In the Paper I, it was demonstrated that there is an increase in the prevalence of 
acquired drug resistance in South Africa from the period 2006 and 2014 and this 
is consistent with earlier reports for LMIC (257, 258). In addition, DSA results 
from the recombinant viruses (derived from the gag-pol gene of predominantly 
HIV-1C and non-C infected patients from the Swedish InfCare cohort), indicate 
a wide range of PI susceptibility specifically for HIV-1C viruses and this agrees 
very well with what has been previously reported (259). The reduced sensitivity 
of some HIV-1C (though not significant) compared to non-C viruses for ATV and 
DRV in contrast to LPV could have multifactorial reasons. For Instance, it could 
be linked to the mechanism of binding. To explain further, even though most 
PIs function by binding in the active site of protease, DRV is an example of an 
exception. DRV has a unique mechanism of action of binding to protease that is 
not common for other PIs and this mechanism proposes that DRV can also bind 
on the surface of one of the enzymes’ flexible flaps in the protease dimer (260). 
Notwithstanding the facts that DRV has a high binding affinity to HIV protease 
(approximately 100-fold than most PIs) (261), a high genetic barrier to resistance 
than most PIs (262) and that clinical studies have also shown the superiority of 
DRV against LPV (263) and ATV (264), there is evidence that DRV can be compro-
mised by single mutations. For example, it has been shown that a single mutation 
in protease V32I can compromise the antiviral activity of DRV substantially (265). 
In addition, in vitro selection experiments have demonstrated the development of 
gag mutations that could affect DRV antiviral activity (196). Hence there might 
be mechanisms of drug resistance that could be specific to either DRV, ATV and 
LPV. Since viruses used in Paper I, lacked primary mutations in the protease gene 
and were derived from treatment-naïve patients, it may be rational to assume that 
naturally occurring polymorphisms (NOPs) or mutation(s) in HIV-1C gag could 
cause phenotypic resistance to PIs in a manner not yet investigated. Furthermore, 
it can be assumed that potential gag mutation(s) may not show cross-resistance 
to PI drugs and be specific in acting on the unique mechanisms each PI may have 
in binding to protease. 
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Paper II continued with the logic to speculate on the role that gag might play in 
influencing PI-based therapeutic response. The observed results for the replication 
fitness of HIV-1C viruses containing the PYxE motif in gag-p6 region compared 
to the wild- type (WT) HIV-1C reinforces the potential importance of gag. Other 
studies have shown similar results (205, 266) 
In Paper III, EFdA was investigated with other NNRTIs and TAF for their in vitro 
potency and subtype-specific response. The broad and subtype-independent  activity 
of EFdA was demonstrated compared to other drugs and EFdA can be recom-
mended as a strong candidate for a long-acting drug that can be administered to 
HIV-1 patients. Proof of concept for the long-acting drug potential of EFdA has 
already been confirmed by a recent report (267) that demonstrated a reduction of 
viral load in animals injected with an implant of EFdA for more than six months. 
Results from Paper III give optimism to the future of ARV therapy for non-B 
subtypes. Considering the challenges HIV-1 infected patients face in adherence 
to existing clinical drugs (268), the potential of long-act formulations could revo-
lutionize the progress of ARV therapy. However, RPV and ETR results were not 
encouraging for their use in an HIV-1C dominated setting. To add on, RPV already 
has a long-acting coformulation with INSTI drug – CAB, that has already entered 
clinical trials (269) and it is worth mentioning that the success of the long-acting 
formulation in a subtype C dominated setting will require close monitoring of 
HIV-1C patients. DRMs, even for those known to cause a reduction in fitness of 
HIV-1 viruses when treated with RPV, can be compensated by single mutations 
that evolve rapidly, leading to the emergence of fit RPV-resistant viruses. For 
instance, it is already known, that the single mutation E138A/K (which reduces 
the fitness of RPV-resistant HIV-1C viruses) can be compensated by the develop-
ment of N348I mutation in the connection domain of RT leading to a E138A/K 
fit resistant virus (270). Hence regimens containing RPV may not be suitable in 
an HIV-1C dominated setting.
To conclude, the World Health Organisation (WHO) has recommended the use 
of INSTIs as part of the regimen for first-line therapy in LMIC (2). Results from 
Paper IV, suggest that second-generation INSTIs are a better option for non-B 
subtypes. However, the occurrence of naturally occurring polymorphisms (NOPs), 
such as M50I, could compromise the efficacy of second-generation INSTIs when 
they occur with known mutations, such as R263K, as recently shown (271). The 
observation of NOPs in HIV-1C integrase that have the potential to impact the effi-
cacy of INSTIs was also reported recently for integrase sequences analyzed from 
South Africa (272). However, more mechanistic studies are needed to demon strate 
the association of NOPs with major INSTI mutations and evaluate the potency of 
INSTIs in treating HIV-1 non-B subtypes.
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6 CONCLUSION AND RECOMMENDATIONS
The following conclusions and recommendations can be drawn from findings in 
this thesis:
• The prevalence of acquired drug resistance in South Africa is increasing, and 
more specifically, the prevalence is increasing for NNRTI and NRTI mutations. 
However, the majority of patients who failed on PI-based second-line treatment 
did not have any PI DRMs. Therefore it is recommended that patients receiving 
PI-based regimens should be monitored closely for adherence. 
• Mutations in the gene or changes in the gag-p6 region could significantly limit 
the options of second-line treatment involving boosted PI in the presence or 
absence of known protease mutations. More research, involving mechanistic 
studies is recommended to identify the role of gag mutations or naturally occur-
ring polymorphisms (NOPs) that affect PI susceptibility. Once the mutations 
are established, genotypic testing assays can be expanded to include the gag 
gene.
• EFdA is a strong candidate to inhibit non-B subtypes and a good candidate 
as a long-acting drug to overcome problems associated with adherence that 
can hamper the success of ARV therapy and lead to the emergence of drug 
resistance. Furthermore, it is recommended that the use of RPV-based regimens 
in an HIV-1C dominated setting should be closely monitored and possibly 
avoided in patients who are in high-risk groups, such people who inject drugs 
(PWID), men who have sex with other men (MSM) and sex workers, where 
there is increased risk of transmitting resistant viruses.
• Finally, it can be concluded that second-generation INSTIs have a high inhibi-
tory potential than first-generation INSTI drugs and, more specifically, in non-B 
subtypes (such as A-like viruses). However, it is recommended that routine 
monitoring and adherence support be given to INSTI HIV-1 patients for the 
surveillance of NOPs that could synergize with know INSTI mutations and 
lead to the emergence of resistance.
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